Vaccine

Cancer Drug Developer BioNTech to Buy Neon Therapeutics in $67M Deal

8 monthes ago   |   By Xconomy

Neon Therapeutics closed 2019 by curtailing its cancer vaccine programs and laying off 24 percent of its workforce, part of a corporate restructuring aimed at finding a new path for the company. That new path will now be as a division of cancer drug developer BioNTech. BioNTech announced Thursday that it has agreed to acquire Cambridge, MA-based Neon in a $67 million stock deal. According to the terms, the BioNTech shares that Neon shareholders will receive value the company at $2.18 per share-a 77.2 premium to Wednesday's closing stock price. When Neon went public less than two years...
Read more ...

 


Search by Tags

   Vaccine      Vaccines      Cancer      Drug      Drugs      Therapeutics      Boston      Boston blog main      Boston top stories      Europe blog main      Europe top stories      National blog main      BioNtech      Biotech      Bristol-myers Squibb      Cancer      Cancer immunotherapy      Cancer Vaccine      CAR-T immunotherapy      Checkpoint inhibitor      Clinical trials      Eli Lilly      Genmab      Life Sciences      Melanoma      Messenger RNA therapeutics      MRNA drugs      Neon Therapeutics      Nivolumab      Pancreatic Cancer      Sanofi  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Bio Roundup: Grail Acquisition, Libra's Launch, Tau Trial Results & More

Bio Roundup: Grail Acquisition, Libra's Launch, Tau Trial Results & More

In biotech, you can go home again. Four years ago, Illumina spun out cancer diagnostics startup Grail. This week, the gene sequencing giant announced it is acquiring Grail in... Read more ...

Combined Therapeutics Wins $250,000 MilliporeSigma Advance Biotech Grant

Combined Therapeutics Wins $250,000 MilliporeSigma Advance Biotech Grant

MilliporeSigma has awarded MIT spin-out Combined Therapeutics a check for $250,000 as the winner of its 2020 Advance Biotech Grant. Combined Therapeutics is an early stage... Read more ...

Machine Learning Takes on Synthetic Biology: Algorithms Can Bioengineer...

Machine Learning Takes on Synthetic Biology: Algorithms Can Bioengineer Cells for You

Tijana Radivojevic and Hector Garcia Martin working on mechanical and statistical modeling, data visualizations, and metabolic maps at the Agile BioFoundry last year. If... Read more ...

And the 2020 National Xconomy Awards Winners Are

And the 2020 National Xconomy Awards Winners Are

Congratulations to all the finalists and winners! This year we received over 600 nominations across 10 award categories. Each nomination was carefully reviewed and ranked by... Read more ...

Talking Alone: Researchers Use Artificial Intelligence Tools to Predict...

Talking Alone: Researchers Use Artificial Intelligence Tools to Predict Loneliness

A team led by researchers at University of California San Diego School of Medicine has used artificial intelligence technologies to analyze natural language patterns to discern... Read more ...

Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs

Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs

Many drugs work by binding to a protein and blocking it. Technology for eliminating disease-causing proteins altogether remains experimental, but this approach has gained... Read more ...

Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders

Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders

Amyotrophic lateral sclerosis has no cure and few available treatments but the past decade has revealed new knowledge about the pathology of the disease. Libra Therapeutics is... Read more ...

Scientists sequence the 92-year-old mold that produced the first antibiotic...

This mold was regrown from Alexander Fleming's frozen sample that produced the first antibiotic, penicillin. Read more ...

What We Know About Coronavirus Cases in K-12 Schools So Far

Schools are not islands, and so it was inevitable that when students and teachers returned this fall to classrooms, coronavirus cases would follow them. Read more ...

Cidara Therapeutics: Senior Clinical Data Manager

Cidara Therapeutics: Position Summary The Senior Clinical Data Manager is responsible for performing data management vendor oversight, complex clinical data review, dis... San... Read more ...